Overview
Thermo Fisher Scientific provides end-to-end contract development and manufacturing organization (CDMO) services for pharmaceuticals, including APIs, biologics, viral vectors, cell and gene therapies, and small molecules from pre-clinical to commercialization. The company operates over 60 global sites with capabilities in sterile fill-finish, oral solid dose production, mRNA lipid nanoparticles, and clinical trial supply chain management. Recent expansions include Accelerator Drug Development solutions integrating CDMO, CRO, and logistics for biotech and large pharma.
Frequently asked questions
- What manufacturing capabilities does Thermo Fisher offer for pharma?
- End-to-end CDMO services covering APIs, biologics, cell/gene therapies, sterile fill-finish in Italy and US, oral solid dose lines in US, Canada, France, plus mRNA and lipid nanoparticle production.
- What is the global reach of Thermo Fisher's pharma services?
- Over 60 sites worldwide, including expansions in Cincinnati (US), Toronto (Canada), Bourgoin (France), Ferentino/Monza (Italy), Plainville (US), with integrated global logistics and CRO capabilities.
- Does Thermo Fisher support regulatory compliance and clinical trials?
- Yes, provides cGMP-compliant manufacturing, clinical research patient enrollment via CRO, Accelerator Drug Development for pre-clinical to commercialization, and supply chain services meeting biopharma regulatory needs.